Download full report with analyst certification and important disclosures
Jan 23 2023, 06:50 GMT
At close of market on Friday January 20th, Symrise released preliminary headline figures for FY22 and announced a €126m loss relating to its interest in Swedencare. Organic growth remains robust at +11.4% (Davy: +10.5%), supported by ongoing strength in the Health, Nutrition & Care division. Profitability was impacted by a softer performance in Scent & Care. The FY22 EBITDA margin (pre-impairment loss) of 20% (Davy: 20.8%) was below its prior guidance of “around 21%”, with FY22 EBITDA 3.4% lower than our current forecasts. Long-term growth and profitability goals were re-affirmed.
Jan 23 2023, 06:50 GMT